MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018

Increased focus where we can create the most value

July – September

Significant events during the quarter

- Positive top-line joint structure outcomes were reported from the MIV-711 osteoarthritis phase II extension study (MIV-711-202). Treatment with MIV-711 over a total 12 months resulted in a continuing treatment effect on joint bone area growth and prevention of cartilage degradation.
- The first patient was enrolled and dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC).
- Dr. Linda Basse was appointed as Chief Medical Officer effective October 1.

Financial summary

- Net turnover totaled SEK 3.0 million (5.1 m).
- The loss before interest, tax, depreciation and amortization (EBITDA) totaled SEK -66.9 million (-78.3m). Basic and diluted earnings per share were SEK -2.93 (-3.94) and -2.93 (-3.94) respectively.
- The cash flow from operating activities amounted to SEK -78.4 million (-63.6 m).
- Liquid assets and short-term investments totaled SEK 357.1 million (557.8 m) at the period end.

January - September

Financial summary

- Net turnover totaled SEK 10.3 million (32.4 m).
- The loss before interest, tax, depreciation and amortization (EBITDA) totaled SEK -229.9 million (-250.1 m). Basic and diluted earnings per share were SEK -9.88 (-11.42) and -9.88 (-11.42) respectively.
- The cash flow from operating activities amounted to SEK -248.1 million (-269.6 m).
- Liquid assets and short-term investments totaled SEK 357.1 million (557.8 m) at the period end.

Significant events after the period end

- Phase Ia clinical study of MIV-818 started in patients with advanced liver cancer. The purpose of this first-in-human trial is to study the safety, tolerability and pharmacokinetics of MIV-818.
- Positive interim data on birinapant in combination with Keytruda®, in patients with advanced solid tumors who have exhausted available treatment options, were announced in October.
- Medivir announced its plans to concentrate its activities on clinical development. As a result, the board has appointed Dr. Uli Hacksell as the company's CEO. Dr. Hacksell, currently on the board of Medivir, succeeded Christine Lind as of October 15.
- On October 17 Medivir notifyed the Public Employment Office of potential employee redundancies impacting 60 positions, mainly within pre-clinical research and administration.

CEO's message

I took office after the end of the quarter, but have closely followed the developments in Medivir since May this year as a board member. I would like to give a brief background to the focusing of the company's business that was communicated in connection with me becoming CEO. It is actually based on the positive development of our pharmaceutical projects in clinical phase. During the quarter, advancements continued with positive news for all of our clinical projects.

Our strong commitment to developing the value of Medivir's drug candidates has led us to concentrate the company's resources on clinical development. It was a difficult but necessary decision announced after the end of the quarter when we also gave notice to the Public Employment Office regarding potential redundancies of 60 positions. It was taken to ensure that our resources are used where we can create the greatest value. The measures are expected to reduce our running costs, excluding the costs of the clinical projects, by about two thirds.

Let me tell you about the development of Medivir's portfolio. At the end of the second quarter, we were able to present a good safety and tolerability profile in our phase II extension study with MIV-711 for the treatment of osteoarthritis. We could also show sustained effects on clinical symptoms based on the preliminary data. This was reinforced by the top-line results presented at the end of July, which showed that treatment with MIV-711 for a total of 12 months resulted in continued good effect on joint bone area growth. During the quarter, the FDA also published preliminary guidelines for the development of disease modifying osteoarthritis treatments. The new guidelines discuss structural changes as treatment goals in clinical trials, and how it could be used for so-called "accelerated approval", which can positively affect the value of MIV-711.

At the beginning of August, our collaboration with Stanford University School of Medicine in California resulted in the first patient being dosed with remetinostat gel 1% in its trial-initiated phase II clinical study with remetinostat in patients with basal cell cancer.

Dialogue with the FDA on the design of Medivir's planned phase III study with remetinostat continued during the quarter. We want to make possible the initiation of a pivotal study that, given good results, can result in market approval for the treatment of patients with early-stage cutaneous T-cell lymphoma.

MIV-818, our proprietary drug for liver cancer, took the final steps towards the clinic and on October 1, the first patient was dosed with MIV-818 in a phase Ia study. The purpose of this first in human trial is to study safety, tolerability and pharmacokinetics of MIV-818 in patients with advanced liver cancer, a fatal disease with very few available treatment options.

A few days later, on October 4, we presented positive safety data and an interesting effect signal after an interim phase I data analysis from the ongoing phase I/II study of birinapant in combination with Keytruda® on cancer patients in advanced stages. In addition to an excellent safety profile, no dose-limiting toxicity was observed in the first three patient groups, and the dose escalation has been continued to the highest planned dose level in the study.

The clinical projects have thus been pursued successfully. It is specifically to ensure our ability to develop and exploit the value contained in our clinical portfolio that we chose to concentrate the business and have taken both uncomfortable and heavy measures as it involves giving notice and reducing Medivir's research.

Medivir's research is of high quality and our employees are excellent. Therefore, we are investigating strategic alternatives for the valuable assets found in our early research.

Medivir is now restructuring into a significantly smaller organization. That we are reducing the running costs by two thirds says a lot. It will also require us to be more agile and flexibile with the ability to work with outsourcing. In the proposed organization there is a high level of competence that also makes me confident we will manage to run the projects cost-effectively.

Finally, I would like to thank Christine Lind for her efforts and continued contributions in the near future.

Medivir's increased focus on clinical development gives us a positive path for the future. I look forward to sharing more information about our progress in the future.

Uli Hacksell
President & CEO

Research and development

Proprietary Pipeline



Partnership Pipeline



Significant R&D events during the quarter

- Positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase II extension study (MIV-711-202). Treatment with MIV-711 over a total 12 months resulted in a continuing treatment effect on joint bone area growth and prevention of cartilage degradation, complementing the acceptable safety and tolerability profile that had previously been reported.
- The first patient has been enrolled and was dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC). This clinical study, which will be conducted at the Stanford University School of Medicine in California, USA, highlights the opportunity for remetinostat to be used in conditions beyond early-stage cutaneous T-cell lymphoma (CTCL).

Significant R&D events after the end of the third quarter

- Phase Ia clinical study of MIV-818 started in patients with liver cancer. The purpose of this first-in-human trial is to study the safety, tolerability and pharmacokinetics of MIV-818 in patients with advanced liver cancer.
- Positive interim data on birinapant in combination with Keytruda®, in patients with advanced solid tumors who have exhausted available treatment options, were announced in October.

R&D Portfolio

- Full descriptions of all Medivir's development projects, including their current status and ongoing studies, can be found on the Medivir website: http://www.medivir.com/our-projects.

Medivir in brief

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda® for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

PROPRIETARY PROJECTS

Remetinostat - *for the treatment of early stage CTCL*.
Cutaneous T-cell lymphoma (CTCL) is a rare form of blood cancer that first shows up in the skin. A key unmet need for patients in the early stages of CTCL is efficacy on cancerous skin lesions and relief from the symptom of significant itching.

Orally or intravenously administered HDAC inhibitors are already known to be effective treatments for CTCL, but these drugs are only used in late stages of the disease because of their significant side effects. Remetinostat, when administered on the skin as a gel, is only active in the skin as it degrades when reaching the blood stream, thus avoiding these side effects. The next step in development is to reach agreement with the US FDA on the design of the phase III clinical trial.

Birinapant – *for the treatment of solid tumors.*
Birinapant is being developed to treat patients with solid tumors, and extend their survival, where existing treatments do not provide sufficient clinical benefit, or where patients no longer have any treatment options at all.

In August 2017, Medivir initiated a clinical phase I/II study of birinapant in combination with Keytruda®, to clinically demonstrate birinapant's effect as a combination treatment for patients with treatment-resistant solid tumors. In October 2018 Medivir announced the results of an interim analysis performed on the the first three groups of patients. No dose-limiting toxicity has been observed, and the dose escalation has been continued to the highest planned dose level in the study. One of the 12 patients in this interim analysis had a confirmed partial response to treatment, which means that the dimensions of their tumor were reduced by 30% or more. Medivir expects to select the recommended dose of birinapant later this year enabling the dose-expansion phase of the study to be initiated. In this phase, patients with large unmet medical needs with treatment-resistant solid tumours will be treated.

MIV-818 – *for the treatment of liver cancers.*
MIV-818 is our internally developed candidate drug for the treatment of liver cancers. It has been designed for the treatment of cancers in the liver, both in its delivery to the liver and in its way of acting, aimed to make it more effective against liver cancer cells specifically.

The Medicines and Healthcare products Regulatory Agency in the United Kingdom gave its approval during the third quarter 2018 for the start of the first clinical trial with MIV-818. The first patient was enrolled and dosed in this phase Ia study, whose purpose is to study the safety, tolerability and pharmacokinetics of MIV-818 in patients with advanced liver cancer, in October.

MIV-711 – *with potential to be the first disease-modifying drug in osteoarthritis.*
Cathepsin K is a protease that breaks down collagen, a protein that plays an important role in the structural integrity of both bone and cartilage. The cathepsin K inhibitor MIV-711 affects the osteoarthritic joint positively by reducing bone resorption and preventing cartilage breakdown.

Positive results from the initial phase II clinical trial were released in September 2017. This was the first time that data demonstrated clinical benefits on both joint bone and cartilage in osteoarthritis patients after only six months of treatment.

Positive top-line results from the MIV-711 phase II extension study were subsequently reported in June 2018. The study met the primary endpoint, demonstrating that MIV-711 200 mg had an acceptable safety and tolerability profile with 6 months of additional treatment, following the initial phase II study (MIV-711-201) 6-month treatment period (12 months in total). In addition, the response level of the positive, non-significant signals on patient-reported pain and other clinical symptoms seen during the initial phase II study were maintained with additional 6 months of treatment in the extension study.

In July 2018, the effect of MIV-711 on joint structure from the extension study were reported. Treatment with MIV-711 over a total 12 months resulted in a continuing treatment effect on joint bone area growth and prevention of cartilage degradation. The accumulated safety data, including the safety and tolerability profile shown in the extension study, along with its effects on joint structure and clinical symptoms of osteoarthritis, support the advancement of MIV-711 into pivotal studies as a disease-modifying osteoarthritis drug.

Discussions with potential commercial partners for future development is ongoing.

Pre clinical reaseach projects - Medivir's approaches to the discovery of novel anticancer drugs is based on its scientific areas of expertise of nucleoside and nucleotide science, and protease inhibitor design.

An example of Medivir's research is the Leukotide project. The aim of the Leukotide project is to develop a better tolerated and more effective agent that can lead to improved treatment outcomes for patients with hematological cancers.

Research at Medivir has shown that inhibition of MALT1 selectively inhibits the development of a group of immune cells called regulatory T (T_{reg}) cells. T_{reg}s act as suppressors of the immune response, and have been

reported to play a role in limiting the anti-tumor immune response in a number of different cancers. Medivir is therefore investigating the potential of selective MALT1 inhibitors as a new small molecule approach to immune-oncology.

PARTNERED PROJECTS

MIV-802 - is a potent, pan-genotypic nucleotide-based inhibitor of the HCV NS5B polymerase, which is currently in preclinical development. Preclinical data indicate that MIV-802 can be used effectively in combination with other classes of antiviral agents for the treatment of HCV, including protease inhibitors and NS5A inhibitors.

Ascletis has licensed the exclusive rights to develop, manufacture and commercialize MIV-802 in Greater China and Trek Therapeutics has licensed these rights for the rest of the world.

Under the terms of both agreements, Medivir received upfront payments, and is entitled to receive milestones based on successful development through commercial launch and tiered royalties on net sales of MIV-802 containing products.

During the second quarter, Ascletis disclosed that it intends to file an IND for MIV-802 (ASC21) in China during 2018.

Financial overview, July – September 2018

Summary of the Group's figures	Q3		Q1 - Q3		Full year
(SEK m)	2018	2017	2018	2017	2017
Net turnover	3.0	5.1	10.3	32.4	36.6
Operating profit before depreciation and amortization (EBITDA)	-66.9	-78.3	-229.9	-250.1	-342.6
Operating profit (EBIT)	-69.3	-80.6	-236.9	-259.2	-362.8
Profit/loss before tax	-71.2	-79.9	-235.9	-256.6	-359.7
Basic earnings per share, SEK	-2.93	-3.94	-9.88	-11.42	-16.40
Diluted earnings per share, SEK	-2.93	-3.94	-9.88	-11.42	-16.40
Net worth per share, SEK	17.39	30.39	17.39	30.39	25.31
Return on equity, %	-62.2	-27.2	-67.1	-29.2	-32.1
Cash flow from operating activities	-78.4	-63.6	-248.1	-269.6	-358.5
Cash and cash equivalents at period end	357.1	557.8	357.1	557.8	467.8

Revenues

Net turnover for the period from July – September was SEK 3.0 million (5.1 m) corresponding to a decrease of SEK 2.1 million attributable to the reduction in royalty income from simeprevir.

Operating expenses

Other external costs totaled SEK -50.6 million (-66.4 m), corresponding to an decrease of SEK 15.8 million which was mainly from lower cost of drug development.

Personnel costs amounted to SEK -20.6 million (-20.1 m) an increase of 0.5 million and the total expenses was SEK -71.2 million (-86.5 m) an decrease of 15.3 million.

Operating profit/loss

The operating profit/loss totaled SEK -69.3 million (-80.6 m), corresponding to an improvement of SEK 11,3 million primarily from lower external costs.

Liquid assets and short-term investments (SEK m)



Financial overview, January – September 2018

Revenues

Net turnover for the period from January – September was SEK 10.3 million (32.4 m) corresponding to a decrease of SEK 22.1 million attributable to the reduction in royalty income from simeprevir.

Operating expenses

Other external costs totaled SEK -171.8 million (-207.3 m), corresponding to an decrease of SEK 35.5 million which was mainly from lower cost of drug development.

Personnel costs amounted to SEK -72.3 million (-79.6 m) and have decreased by SEK 7.3 million in comparison with the same period last year due to the reorganization implemented during 2016. The total expenses totaled SEK -244.1 million (-286.9 m).

Operating profit/loss

The operating profit/loss totaled SEK -236.9 million (-259.2 m), corresponding to an improvement of SEK 22.3 million from lower external- and personnel costs.

Cash flow, investments, and financial position

Liquid assets, including short-term investments amounted to SEK 357.1 million (557.8 m) at the end of the period, corresponding to a decrease of SEK 200.7 million. The opening balance 2018 was SEK 467.8 million (1,698.5 m).

Medivir's financial assets are, in accordance with its financial policy, invested in low-risk, interest-bearing securities.

Cash flow from operating activities totaled SEK -248.1 million (-269.6 m), with changes in working capital accounting for SEK -13.2 million (-12.0 m) of this total.

Cash flow from financing activities totaled SEK 144.9 million (-858.7 m) and are mainly derived from the directed share issuance in the first quarter. The period's investments in tangible and intangible fixed assets totaled SEK -6.7 million (-12.2 m) and are associated with IT systems, facility improvements and research and office equipment.

Other disclosures, January – September 2018

Employees

Medivir had 73 (91) employees (FTEs) at the period end, 50% (55%) of whom were women. Out of these employees, there are 0 (20) who have been given notice of termination of employment, but whose employment has not yet been terminated.

After the period end Medivir notifyed the Public Employment Office of potential employee redundancies impacting 60 positions, mainly within pre-clinical research and administration.

Share-related incentive plans

To enable the staff to take part of and contribute to a positive value development for the company and to improve the possibilities for the company to keep and employ new competent and dedicated staff the board of directors proposed and the 2017 AGM approved a long term incentive program. The right to subscribe is vested in all of the company's senior executives and other permanent employees of Medivir. The market value was determined using the Black & Scholes valuation model, based on term, strike price, weighted share price during the subscription period (VWAP), risk-free interest rate, and volatility. The subscription price for all outstanding warrants (strike price) per share shall correspond to 133 percent of the volume weighted average rate of the class B share according to the official NASDAQ Stockholm price list during the period.

Medivir employees bought 48 515 warrants during the second quarter 2017 as part of this incentive program. The warrants were issued at a market value of SEK 9.41 each with an exercise price of SEK 89.36 per share. In the fourth quarter 2017, Medivir employees bought an additional 9 320 warrants. These warrants were issued at a market value of SEK 3.98 each with an exercise price of SEK 89.36 per share. The total 57 835 warrants may be exercised to subscribe for new class B shares during the period from 16 December 2020 up to and including 15 January 2021. The valuation calculation for 2017 was based on the following figures: term, 3.66 years; strike price, SEK 89.36; VWAP, SEK 67.19; risk-free interest rate, –0.35 percent; volatility, 32 percent.

In May 2018, the board of directors proposed and the AGM approved a new long term incentive program, in the same manner as 2017. During the second quarter 2018, Medivir employees bought 51 864 warrants at a market value of 5.63 each with an exercise price of SEK 52.75 per share. The warrants may be exercised to subscribe for new class B shares during the period from 16 December 2021 up to and including 15 January 2022. The valuation calculation for 2018 was based on the following figures: term, 3.66 years; strike price, SEK 52.75; VWAP, SEK 39.66; risk-free interest rate, –0.16 percent; volatility, 32 percent.

The Parent Company in brief

Medivir AB (publ.), corporate ID no. 556238-4361, is the Parent Company of the Group. Its operations consist of research and development, and administrative and company management functions.

The Parent Company's total revenues amounted to SEK 8.5 million (33.6 m).

The operating profit/loss was SEK -238.4 million (-259.9 m), corresponding to an improved result of SEK 21.5 million. Combined operating expenses totaled SEK -246.9 million (-293.5 m).

Net financial items totaled SEK 1.3 million (2.9 m), corresponding to a decrease of SEK 1.6 million.

The tax for the period totaled SEK 0 million (-0.6 m). The net profit/loss for the period was SEK -237.1 million (-257.7 m), corresponding to a improvement of SEK 20.6 million.

Liquid assets, including short-term investments with a maximum term of three months, amounted to SEK 348.5 million (549.2 m).

See the section entitled "Financial overview" for additional comments on the operations.

Transactions with related parties

Transactions with related parties are on market terms. There are existing agreements between companies owned by senior executives and Medivir, dating from 2005, which entitle the senior executives to royalties on products that the company may develop based on patented inventions that the company has purchased from the parties in question. During the period, transactions with related parties totaled SEK 0.0 million (0.2 m), attributable to royalty payments to Uppsala Hallbechem AB (Board Member, Anders R Hallberg). No other services were purchased by the company from related parties during the period.

Significant risks and uncertainty factors

An effective risk assessment reconciles Medivir's business opportunities and results with the requirements of shareholders and other stakeholders for stable, long-term value growth and control. The process of pharmaceutical research and development, all the way up to regulatory market approval, is both high-risk and capital-intensive. The majority of projects initiated will never achieve market authorization. If competing pharmaceuticals take market shares, or competing research projects achieve better efficacy and reach the market more quickly, the future value of Medivir's product and project portfolio may be lower than expected. Medivir's success in developing medicines, to

enter into partnerships and to secure funding for its operations, are decisive in terms of the company's future.

A more detailed description of the exposure to risk, and of the ways in which Medivir manages it, is provided in the 2017 Annual Report, see pages 40-41 and in Note 7 on pages 63-65. The Annual Report is available on the company's website: www.medivir.com.

Outlook

Medivir's future investments will mainly be in clinical pharmaceutical projects within oncology.

Huddinge, 26 October 2018

Uli Hacksell
President and CEO

This report has been subject to auditors' review.

The information in this report comprises the information that Medivir is obliged to disclose under the provisions of the Swedish Securities Markets Act.

The information was submitted for publication at 08.30 CET on 26 October 2018.

Financial calendar:

Year End Report (January – December 2018)
February 14, 2019
Interim Report (January – March 2019)
May 3, 2019
Annual General Meeting
May 9, 2019

For further information, please contact
Uli Hacksell, CEO, +46 (0) 8 5468 3100
Erik Björk, CFO, +46 (0)72-228 2831

Notes

Accounting principles

Medivir prepares its Consolidated Accounts in accordance with IFRS, International Financial Reporting Standards, as endorsed by the EU. In addition to the stated IFRS, the Group also observes the Swedish Financial Reporting Board's recommendation, RFR 1 Supplementary Accounting Rules for Groups, and applicable pronouncements from the Swedish Financial Reporting Board. The Group utilizes the acquisition value for Balance Sheet item valuation, unless otherwise indicated. IFRS are under constant development. New standards and interpretations are published on an ongoing basis. Assessments of the impact on Medivir's financial statements due to introduction of new standards and statements are made as appropriate and commented on. Comments are restricted to those changes that have had, or could have, a significant effect on Medivir's accounting.

The revenues in 2018 is related to the royalty from Janssens world wide sales of simeprevir and Glaxo Smith Klines sales of Xerclear in Europe.

The company's management of financial instruments (assets) held at and measured at fair value is described on page 54 and 63-65 in the annual report 2017. There has not been any change in measurement technique and no change in the classification of these assets regarding the fair value hierarchy.

New and revised standards

IFRS 15 Revenue from Contracts with Customers, replaces all previously issued standards and interpretations concerning revenues in a unified revenue recognition model. The company has applied the new standard, as of 1 January 2018, and has evaluated IFRS 15 and its effects on the consolidated accounts. The evaluation has shown that no change is needed, other than in the form of additional disclosure requirements, which will be described in more detail in

the forthcoming annual report. IFRS 9 Financial Instruments, addresses the recognition of financial assets and liabilities and replaces IAS 39 Financial Instruments:

Recognition and Measurement. The Group has applied the new standard, as of 1 January 2018, and has evaluated IFRS 9 and its effects on the consolidated accounts. The evaluation has shown that IFRS 9 will have no effect on the company's profit/loss and financial position. Additionally, no changes to the Note on financial instruments are expected. From January 2019 IFRS 16 will be applicable. The effects are under evaluation and will be disclosed in the year end report.

Consolidated Income Statement, summary	Q3		Q1 - Q3		Full year
(SEK m)	2018	2017	2018	2017	2017
Continuing operations					
Net turnover	3.0	5.1	10.3	32.4	36.6
Other operating income	1.3	3.1	5.5	7.5	9.9
Total income	**4.4**	**8.2**	**15.8**	**39.9**	**46.5**
Merchandise	-	-	-	-1.7	-1.7
Other external expenses	-50.6	-66.4	-171.8	-207.3	-281.1
Personnel costs	-20.6	-20.1	-72.3	-79.6	-104.9
Depreciations and write-downs	-2.4	-2.3	-7.0	-9.1	-20.3
Other operating expenses	0.0	-	-1.5	-1.4	-1.4
Operating profit/loss	**-69.3**	**-80.6**	**-236.9**	**-259.2**	**-362.8**
Net financial items	-1.9	0.7	1.0	2.6	3.1
Profit/loss after financial items	**-71.2**	**-79.9**	**-235.9**	**-256.6**	**-359.7**
Tax	0.0	0.0	0.2	-0.5	-0.5
Net profit/loss for the period	**-71.2**	**-79.9**	**-235.7**	**-257.1**	**-360.2**
Net profit/loss for the period attributable to:					
Parent Company shareholders	-71.2	-79.9	-235.7	-257.1	-360.2
Earnings per share, calculated from the net profit/loss attributable to Parent Company shareholders during the period					
Earnings per share (SEK per share)					
- Total operations, basic earnings	-2.93	-3.94	-9.88	-11.42	-16.40
- Total operations, diluted earnings	-2.93	-3.94	-9.88	-11.42	-16.40
Average number of shares, '000	24 288	20 308	23 846	22 515	21 963
Average number of shares after dilution '000	24 288	20 356	23 846	22 563	22 021
Number of shares at period end, '000	24 288	20 308	24 288	20 308	20 308

Consolidated Statement of Comprehensive Income	Q3		Q1 - Q3		Full year
(SEK m)	2018	2017	2018	2017	2017
Net profit/loss for the period	**-71.2**	**-79.9**	**-235.7**	**-257.1**	**-360.2**
Other comprehensive income					
Exchange rate differences	0.3	0.5	-0.9	0.5	0.0
Total other comprehensive income	**0.3**	**0.5**	**-0.9**	**0.5**	**0.0**
Total comprehensive income for the period	**-70.9**	**-79.4**	**-236.6**	**-256.6**	**-360.2**

Consolidated Balance Sheet, summary

(SEK m)	30-sep 2018	30-sep 2017	31-dec 2017
Assets			
Intangible fixed assets	110.8	121.1	112.8
Tangible fixed assets	16.0	15.8	14.4
Current receivables	19.8	36.0	21.2
Short-term investments	320.8	409.1	409.2
Cash and cash equivalents	36.4	148.7	58.6
Total assets	**503.7**	**730.7**	**616.2**
Shareholders' equity and liabilities			
Shareholders' equity	422.3	617.1	514.1
Current liabilities	81.4	113.7	102.1
Total shareholders' equity and liabilities	**503.7**	**730.7**	**616.2**

Consolidated Statement of Changes in Equity

(SEK m)	Share capital	Other paid-in capital	Exchange rate difference	Accum. loss	Total equity
Opening balance, 1 January 2017	**157.2**	**1 153.4**	**-3.1**	**425.4**	**1 732.9**
Total comprehensive income for the period	-	-	0.5	-257.6	-257.1
Redemption program	-38.7	-818.8	-	-	-857.5
Stock dividend issue	39.3	-39.3	-	-	-
Warrants	-	0.5	-	-	0.5
Transaction costs	-	-	-	-1.7	-1.7
Closing balance, 30 September 2017	**157.7**	**295.8**	**-2.5**	**166.0**	**617.1**
Opening balance, 1 January 2017	**157.2**	**1 153.4**	**-3.1**	**425.4**	**1 732.9**
Total comprehensive income for the period	-	-	0.0	-360.2	-360.2
Redemption program	-38.7	-818.8	-	-	-857.5
Stock dividend issue	39.3	-39.3	-	-	-
Warrants	-	0.5	-	-	0.5
Transaction costs	-	-	-	-1.7	-1.7
Closing balance, 31 December 2017	**157.7**	**295.9**	**-3.0**	**63.5**	**514.1**
Opening balance, 1 January 2018	**157.7**	**295.9**	**-3.0**	**63.5**	**514.1**
Total comprehensive income for the period	-	-	-0.9	-235.7	-236.6
Share issue	30.8	124.0	-	-	154.8
Warrants	-	0.3	-	-	0.3
Transaction costs	-	-	-	-10.2	-10.2
Closing balance, 30 September 2018	**188.5**	**420.1**	**-3.9**	**-182.4**	**422.4**

Consolidated Cash Flow Statement, summary

(SEK m)	Q3 2018	Q3 2017	Q1 - Q3 2018	Q1 - Q3 2017	Full Year 2017
Cash flow from operating activities before changes in working capital	**-70.0**	**-88.2**	**-234.9**	**-257.6**	**-346.9**
Changes in working capital	-8.3	24.6	-13.2	-12.0	-11.6
Cash flow from operating activities	**-78.4**	**-63.6**	**-248.1**	**-269.6**	**-358.5**
Investing activities					
Acquisition/sale of fixed assets	-2.8	-0.9	-6.7	-12.2	-13.5
Cash flow from investing activities	**-2.8**	**-0.9**	**-6.7**	**-12.2**	**-13.5**
Financing activities					
Redemption program	-	-0.5	-	-857.5	-857.5
Warrants	-	0.5	0.3	0.5	0.5
Share issue	-	-	154.8	-	-
Transaction costs	-0.2	-1.7	-10.2	-1.7	-1.7
Cash flow from financing activities	**-0.2**	**-1.7**	**144.9**	**-858.7**	**-858.6**
Cash flow for the period	**-81.4**	**-66.2**	**-109.9**	**-1 140.5**	**-1 230.7**
Cash and cash equivalents at beginning of period	438.6	624.1	467.8	1 698.5	1 698.5
Exchange rate difference, liquid assets	-0.1	-0.1	-0.8	-0.1	-
Cash and cash equivalents at end of period	**357.1**	**557.8**	**357.1**	**557.8**	**467.8**

Parent company income statement, summary

(SEK m)	Q3 2018	Q3 2017	Q1 - Q3 2018	Q1 - Q3 2017	Full year 2017
Net turnover	3.0	5.1	10.3	32.4	38.5
Other operating income	-1.0	1.0	-1.8	1.2	1.2
Total income	**2.0**	**6.1**	**8.5**	**33.6**	**39.7**
Merchandise	-	-	-	-1.7	-1.7
Other external expenses	-48.7	-65.0	-165.8	-201.7	-273.7
Personnel costs	-20.6	-20.1	-72.6	-79.6	-104.9
Depreciations and write-downs	-2.4	-2.3	-7.0	-9.1	-20.3
Other operating expenses	0.0	-	-1.5	-1.4	-1.4
Operating profit/loss	**-69.7**	**-81.3**	**-238.4**	**-259.9**	**-362.2**
Profit/loss from participation in Group companies	-	-	-	-	-1.9
Net financial items	-1.8	0.8	1.3	2.9	3.4
Profit/loss after financial items	**-71.5**	**-80.5**	**-237.2**	**-257.0**	**-360.7**
Tax	-	-	0.0	-0.6	-0.6
Net profit/loss for the period (=comprehensive income)	**-71.5**	**-80.5**	**-237.1**	**-257.7**	**-361.3**

Parent company balance sheet, summary (SEK m)	30-sep 2018	30-sep 2017	31-dec 2017
Assets			
Intangible fixed assets	110.8	121.1	112.7
Tangible fixed assets	16.0	15.8	14.4
Shares in subsidiaries	0.1	0.1	0.1
Receivables on Group companies	23.6	21.9	24.3
Current receivables	15.1	34.4	19.5
Short-term investments	320.8	409.1	409.2
Cash and bank balances	27.7	140.2	49.4
Total assets	**514.2**	**742.5**	**629.7**
Shareholders' equity and liabilities			
Shareholders' equity	415.6	612.9	509.3
Provisions	0.2	13.6	7.1
Liabilities to Group companies	21.7	20.4	22.8
Current liabilities	76.7	95.5	90.6
Total shareholders' equity and liabilities	**514.2**	**742.5**	**629.7**

Key ratios, share data, options	Q3		Q1 - Q3		Full year
	2018	2017	2018	2017	2017
Return on:					
- shareholders' equity, %	-62.2	-27.2	-67.1	-29.2	-32.1
- capital employed, %	-62.1	-48.6	-67.2	-29.1	-32.0
- total capital, %	-52.2	-41.2	-56.2	-25.8	-28.3
Number of shares at beginning of period, '000	24 288	20 319	20 319	26 966	26 966
Number of shares at period end, '000	24 288	20 319	24 288	20 319	20 319
- of which class A shares	-	475	-	475	475
- of which class B shares	24 288	19 833	24 288	19 833	19 833
- of which repurchased B shares	-	11	-	11	11
Average number of shares, '000	24 288	20 308	23 846	22 515	21 963
Outstanding warrants, '000	110	49	110	49	58
Share capital at period end, SEK m	188.5	157.7	188.5	157.7	157.7
Shareholders' equity at period end, SEK m	422.3	617.1	422.3	617.1	514.1
Earnings per share, SEK					
- Total operations, basic earnings	-2.93	-3.94	-9.88	-11.42	-16.40
- Total operations, diluted earnings	-2.93	-3.94	-9.88	-11.42	-16.40
Shareholders' equity per share, SEK	17.39	30.39	17.39	30.39	25.31
Net worth per share, SEK	17.39	30.39	17.39	30.39	25.31
Cash flow per share after investments, SEK	-3.34	-3.18	-10.68	-12.52	-16.94
Equity/assets ratio, %	83.8	84.4	83.8	84.4	83.4
EBITDA	-66.9	-78.3	-229.9	-250.1	-342.6
EBIT	-69.3	-80.6	-236.9	-259.2	-362.8

Key ratio definitions

Average number of shares. The unweighted average number of shares during the period.
Basic earnings per share. Profit/loss per share after tax divided by the average number of shares.
Capital employed. Balance Sheet total less non-interest-bearing liabilities including deferred tax liabilities.
Cash flow per share after investments. Cash flow after investments divided by the average number of shares.
Diluted earnings per share. Profit/loss per share after tax divided by the average number of shares and outstanding warrants adjusted for any dilution effect.
EBIT (Earnings before interest and taxes). Operating profit/loss after depreciation and amortization.
EBITDA (Earnings before interest, taxes, depreciation and amortization). Operating profit/loss before depreciation and amortization.
Equity/assets ratio. Shareholders' equity in relation to the Balance Sheet total.
Net worth per share. Shareholders' equity plus hidden assets in listed equities divided by the number of shares at the period end.
Operating margin. Operating profit/loss as a percentage of net turnover.
Return on capital employed. Profit/loss after financial items plus interest expenses as a percentage of the average capital employed.
Return on shareholders' equity. Profit/loss after tax as a percentage of the average shareholders' equity.
Return on total assets. Profit/loss after financial items plus interest expenses as a percentage of the average Balance Sheet total.
Shareholders' equity per share. Shareholders' equity divided by the number of shares at the period end.

The above key ratios are deemed to be relevant for the type of operations conducted by Medivir and to contribute to an increased understanding of the financial report.

AUDITOR'S REPORT

Medivir AB (publ), corp. reg. no. 556238-4361.

Introduction

We have reviewed the condensed interim financial information (interim report) of Medivir AB (publ) as of 30 September 2018 and the nine-month period then ended. The board of directors and the CEO are responsible for the preparation and presentation of the interim financial information in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, *Review of Interim Report Performed by the Independent Auditor of the Entity*. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, ISA, and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act, regarding the Group, and with the Swedish Annual Accounts Act, regarding the Parent Company.

Stockholm, 26 October 2018

Öhrlings PricewaterhouseCoopers AB

Tobias Stråhle
Authorized Public Accountant